Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Fitch Rates Teva's Euro Bond Offering 'BBB+'

      Headlines

      Tue, 24 Mar 2015

      a 'BBB+' rating to the unsecured Euro bond offering issued by Teva Pharmaceutical Finance Netherlands II, B.V. (Israel) part of Teva Pharmaceuticals Industries Ltd. ( Teva ). Proceeds are expected to be used for general corporate purposes

    2. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      vertical integration than its larger global competitors Teva TEVA and Mylan MYL. Four major deals for a combined total of ..... solidified its ranking as a generics industry leader along with Teva , Sandoz (a subsidiary of Novartis NVS), and Mylan

    3. BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia

      Headlines

      Wed, 4 Mar 2015

      March 4 (Reuters) - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and

    4. Appleseed Letter to Shareholders

      Headlines

      Mon, 23 Feb 2015

      Appleseed Fund has generated an annualized return of 7.19% per annum. We had a few big winners in 2015, namely Teva Pharmaceuticals ( TEVA ) and John B. Sanfilippo (JBSS), but the returns from these winners were more than offset by companies with

    5. Momenta Faces Setbacks as Generic Copaxone Opportunity Nears

      Commentary

      Tue, 17 Feb 2015

      the timing of Momenta’s potential generic Copaxone launch, Teva ’s ability to aggressively convert patients to its new formulation ..... S. Food and Drug Administration approves a generic version. Teva already has over 60% of patients on the new formulation, a

    6. Mesoblast First-Half Result as Expected; Seeking Partners for Late-Stage Pipeline

      Commentary

      Thu, 12 Feb 2015

      upfront payment of USD 130 million and is eligible for up to USD 1,700 million in milestone payments through its alliance with Teva Pharmaceuticals, for its cardiovascular system programs now in phase III. Our fair value estimate is unchanged at AUD 7.00

    7. Teva's internal investigation finds possible corruption

      Headlines

      Wed, 11 Feb 2015

      Feb 11 (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.

    8. Teva Meets Expectations as It Prepares for Challenging 2015

      Commentary

      Thu, 5 Feb 2015

      changes to our fair value estimate for Teva after the company’s fourth-quarter ..... continue to drive modest earnings growth for Teva , but the high likelihood of a generic Copaxone ..... patents likely buys some additional time for Teva to transition patients to its newer formulation

    9. Amgen's Biosimilar Headwinds Poised to Increase in 2015, but We're Bullish on Upcoming Launches

      Commentary

      Wed, 28 Jan 2015

      Amgen has been mild, but should accelerate to eventual double-digit sales declines in the anemia and neutropenia franchises. Teva 's branded neutropenia drug Granix is still struggling to gain market share against Neupogen, and Amgen's upcoming launch

    10. 2014's Biggest Stock Winners: Is There Any Gas Left in the Tank?

      Headlines

      Wed, 7 Jan 2015

      Mallinckrodt, as a smaller player within the generics space, doesn't have the scale to compete with giants such as Teva TEVA and Mylan MYL. The stock's valuation isn't attractive, either, trading well above Krempa's $72 fair value estimate

    « Prev12345Next »
    Content Partners